Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group.

Lancet Neurol. 2019 Sep;18(9):834-844. doi: 10.1016/S1474-4422(19)30200-5.

PMID:
31397289
2.

Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy.

Lim J, Rietveld A, De Bleecker JL, Badrising UA, Saris CGJ, van der Kooi AJ, de Visser M.

Neurol Neuroimmunol Neuroinflamm. 2018 Oct 16;6(1):e513. doi: 10.1212/NXI.0000000000000513. eCollection 2019 Jan.

3.

FSHD type 2 and Bosma arhinia microphthalmia syndrome: Two faces of the same mutation.

Mul K, Lemmers RJLF, Kriek M, van der Vliet PJ, van den Boogaard ML, Badrising UA, Graham JM Jr, Lin AE, Brand H, Moore SA, Johnson K, Evangelista T, Töpf A, Straub V, Kapetanovic García S, Sacconi S, Tawil R, Tapscott SJ, Voermans NC, van Engelen BGM, Horlings CGC, Shaw ND, van der Maarel SM.

Neurology. 2018 Aug 7;91(6):e562-e570. doi: 10.1212/WNL.0000000000005958. Epub 2018 Jul 6.

4.

Teaching NeuroImages: A protruding asymmetrical belly.

Straathof CSM, Badrising UA.

Neurology. 2017 Dec 12;89(24):e288-e289. doi: 10.1212/WNL.0000000000004738. No abstract available.

PMID:
29229693
5.

Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis.

Badrising UA, Tsonaka R, Hiller M, Niks EH, Evangelista T, Lochmüller H, Verschuuren JJ, Aartsma-Rus A, Spitali P.

J Neuromuscul Dis. 2017;4(4):327-335. doi: 10.3233/JND-170234.

PMID:
29172005
6.

Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

Lilleker JB, Rietveld A, Pye SR, Mariampillai K, Benveniste O, Peeters MT, Miller JA, Hanna MG, Machado PM, Parton MJ, Gheorghe KR, Badrising UA, Lundberg IE, Sacconi S, Herbert MK, McHugh NJ, Lecky BR, Brierley C, Hilton-Jones D, Lamb JA, Roberts ME, Cooper RG, Saris CG, Pruijn GJ, Chinoy H, van Engelen BG; all UKMYONET contributors.

Ann Rheum Dis. 2017 May;76(5):862-868. doi: 10.1136/annrheumdis-2016-210282. Epub 2017 Jan 25.

7.

Interventions for dysphagia in long-term, progressive muscle disease.

Jones K, Pitceathly RD, Rose MR, McGowan S, Hill M, Badrising UA, Hughes T.

Cochrane Database Syst Rev. 2016 Feb 9;2:CD004303. doi: 10.1002/14651858.CD004303.pub4. Review.

PMID:
26859621
8.

A protocol to develop clinical guidelines for inclusion-body myositis.

Jones KL, Sejersen T, Amato AA, Hilton-Jones D, Schmidt J, Wallace AC, Badrising UA, Rose MR; IBM Guideline Development Group.

Muscle Nerve. 2016 Apr;53(4):503-7. doi: 10.1002/mus.25036. Epub 2016 Feb 22. Review.

9.

Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.

Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, Lamb JA, Cooper RG, Roberts M, Badrising UA, De Bleecker JL, Machado PM, Hanna MG, Plestilova L, Vencovsky J, van Engelen BG, Pruijn GJ.

Ann Rheum Dis. 2016 Apr;75(4):696-701. doi: 10.1136/annrheumdis-2014-206691. Epub 2015 Feb 24.

10.

Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.

Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, Verbeek MM, Badrising UA, Arnardottir S, Gheorghe K, Lundberg IE, Boelens WC, van Engelen BG, Pruijn GJ.

Ann Neurol. 2013 Mar;73(3):397-407. doi: 10.1002/ana.23822. Epub 2013 Mar 4.

PMID:
23460448
11.

A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.

Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA.

Brain. 2011 Nov;134(Pt 11):3167-75. doi: 10.1093/brain/awr217. Epub 2011 Sep 9.

PMID:
21908393
12.

Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis.

Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA.

Rheumatology (Oxford). 2011 Jun;50(6):1153-61. doi: 10.1093/rheumatology/ker001. Epub 2011 Feb 2.

PMID:
21288962
13.

Clinical reasoning: a 70-year-old man with walking difficulties.

Cox FM, Verschuuren JJ, Badrising UA.

Neurology. 2010 Nov 9;75(19):e80-4. doi: 10.1212/WNL.0b013e3181fc27ac. No abstract available.

PMID:
21060089
14.

TREX1 mutations are not associated with sporadic inclusion body myositis.

Cox FM, Boon EM, van der Lans CA, Bakker E, Verschuuren JJ, Badrising UA.

Eur J Neurol. 2010 Aug;17(8):1108-9. doi: 10.1111/j.1468-1331.2010.02964.x. Epub 2010 Feb 23.

PMID:
20192983
15.

The heart in sporadic inclusion body myositis: a study in 51 patients.

Cox FM, Delgado V, Verschuuren JJ, Ballieux BE, Bax JJ, Wintzen AR, Badrising UA.

J Neurol. 2010 Mar;257(3):447-51. doi: 10.1007/s00415-009-5350-9. Epub 2009 Oct 8.

16.

Detecting dysphagia in inclusion body myositis.

Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA.

J Neurol. 2009 Dec;256(12):2009-13. doi: 10.1007/s00415-009-5229-9. Epub 2009 Jul 15.

17.

Association of the leukocyte immunoglobulin G (Fcgamma) receptor IIIa-158V/F polymorphism with inflammatory myopathies in Dutch patients.

Bronner IM, Hoogendijk JE, de Visser M, van de Vlekkert J, Badrising UA, Wintzen AR, Uitdehaag BM, Blokland-Fromme M, Leusen JH, van der Pol WL.

Tissue Antigens. 2009 Jun;73(6):586-9. doi: 10.1111/j.1399-0039.2009.01236.x.

PMID:
19493236
18.

Synaptic dysfunction does not contribute to muscle weakness in inclusion-body myositis.

Badrising UA, Verschuuren JJ, Wintzen AR, van Dijk JG.

Muscle Nerve. 2007 Feb;35(2):266-7. No abstract available.

PMID:
17143892
19.

Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Badrising UA, Maat-Schieman ML, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, Verschuuren JJ, Wintzen AR.

J Neurol. 2005 Dec;252(12):1448-54. Epub 2005 Jun 17.

PMID:
15942703
20.

Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis.

Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, Maat-Schieman ML, van Doorn P, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, van Duinen SG; Dutch IBM Study Group.

Neurology. 2004 Dec 28;63(12):2396-8.

PMID:
15623710
21.

Decremental response of the nasalis and hypothenar muscles in myasthenia gravis.

Niks EH, Badrising UA, Verschuuren JJ, Van Dijk JG.

Muscle Nerve. 2003 Aug;28(2):236-8.

PMID:
12872330
22.

Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.

Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, van Doorn PA, van Engelen BG, Hoogendijk JE, Höweler CJ, de Jager AE, Jennekens FG, Koehler PJ, de Visser M, Viddeleer A, Verschuuren JJ, Wintzen AR.

Ann Neurol. 2002 Mar;51(3):369-72.

PMID:
11891832
23.

Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis.

van der Meulen MF, Hoogendijk JE, Moons KG, Veldman H, Badrising UA, Wokke JH.

Neuromuscul Disord. 2001 Jul;11(5):447-51.

PMID:
11404115
24.

Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.

Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, van den Hoogen F, Hoogendijk J, Höweler C, de Jager A, Jennekens F, Koehler P, van der Leeuw H, de Visser M, Verschuuren JJ, Wintzen AR.

Neurology. 2000 Nov 14;55(9):1385-7.

PMID:
11087787
25.

Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis.

Hengstman GJ, van Engelen BG, Badrising UA, van den Hoogen FH, van Venrooij WJ.

Ann Neurol. 1998 Sep;44(3):423. No abstract available.

PMID:
9749616
26.

['Inclusion body'-myositis].

Badrising UA, Maat-Schieman ML, van Duinen SG, van Dijk JG, Verschuuren JJ, Wintzen AR.

Ned Tijdschr Geneeskd. 1998 Mar 14;142(11):553-7. Dutch.

PMID:
9623110
27.

Influence of bolus volume on hyoid movements in normal individuals and patients with Parkinson's disease.

Wintzen AR, Badrising UA, Roos RA, Vielvoye J, Liauw L.

Can J Neurol Sci. 1994 Feb;21(1):57-9.

PMID:
8180907
28.

Dysphagia in ambulant patients with Parkinson's disease: common, not dangerous.

Wintzen AR, Badrising UA, Roos RA, Vielvoye J, Liauw L, Pauwels EK.

Can J Neurol Sci. 1994 Feb;21(1):53-6.

PMID:
8180906

Supplemental Content

Loading ...
Support Center